Evidence map›Paper›PMID 22699894›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2012

Brain-derived neurotrophic factor activation of CaM-kinase kinase via transient receptor potential canonical channels induces the translation and synaptic incorporation of GluA1-containing calcium-permeable AMPA receptors.

Dale A Fortin, Taasin Srivastava, Diya Dwarakanath, Philippe Pierre, Sean Nygaard, Victor A Derkach, Thomas R Soderling

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dale A FortinVollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA. fortind@ohsu.edu
Taasin Srivastava
Diya Dwarakanath
Philippe Pierre
Sean Nygaard
Victor A Derkach
Thomas R Soderling
Oregon Health & Science University · USAix-Marseille Université · FRVollum Institute · US

Funding

REGULATORY PHOSPHORYLATION OF GLUTAMATE RECEPTORSR01NS027037 · NINDS · VANDERBILT UNIVERSITY · PI SODERLING, THOMAS R · 1989 to 2011
$3.9M
NINDS NIH HHS NS027037NINDS NIH HHS R01 NS027037
6 · The paper itself

Abstract

Glutamatergic synapses in early postnatal development transiently express calcium-permeable AMPA receptors (CP-AMPARs). Although these GluA2-lacking receptors are essential and are elevated in response to brain-derived neurotrophic factor (BDNF), little is known regarding molecular mechanisms that govern their expression and synaptic insertion. Here we show that BDNF-induced GluA1 translation in rat primary hippocampal neurons requires the activation of mammalian target of rapamycin (mTOR) via calcium calmodulin-dependent protein kinase kinase (CaMKK). Specifically, BDNF-mediated phosphorylation of threonine 308 (T308) in AKT, a known substrate of CaMKK and an upstream activator of mTOR-dependent translation, was prevented by (1) pharmacological inhibition of CaMKK with STO-609, (2) overexpression of a dominant-negative CaMKK, or (3) short hairpin-mediated knockdown of CaMKK. GluA1 surface expression induced by BDNF, as assessed by immunocytochemistry using an extracellular N-terminal GluA1 antibody or by surface biotinylation, was impaired following knockdown of CaMKK or treatment with STO-609. Activation of CaMKK by BDNF requires transient receptor potential canonical (TRPC) channels as SKF-96365, but not the NMDA receptor antagonist d-APV, prevented BDNF-induced GluA1 surface expression as well as phosphorylation of CaMKI, AKT(T308), and mTOR. Using siRNA we confirmed the involvement of TRPC5 and TRPC6 subunits in BDNF-induced AKT(T308) phosphorylation. The BDNF-induced increase in mEPSC was blocked by IEM-1460, a selected antagonist of CP-AMPARs, as well as by the specific repression of acute GluA1 translation via siRNA to GluA1 but not GluA2. Together these data support the conclusion that newly synthesized GluA1 subunits, induced by BDNF, are readily incorporated into synapses where they enhance the expression of CP-AMPARs and synaptic strength.

Indexed as

2-Amino-5-phosphonovalerateAdamantaneAnimalsBenzimidazolesBrain-Derived Neurotrophic FactorCalcium-Calmodulin-Dependent Protein Kinase KinaseCalcium Channel BlockersEnzyme InhibitorsExcitatory Amino Acid AntagonistsFemaleGene Knockdown TechniquesHippocampusImidazolesMaleMiniature Postsynaptic PotentialsNaphthalimides1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole2-Amino-5-phosphonovalerateAdamantaneBenzimidazolesBrain-Derived Neurotrophic FactorCalcium-Calmodulin-Dependent Protein Kinase KinaseCalcium Channel BlockersEnzyme InhibitorsExcitatory Amino Acid AntagonistsIEM 1460ImidazolesmTOR protein, ratNaphthalimidesReceptors, AMPARNA, Small InterferingSTO 609TOR Serine-Threonine KinasesTrpc5 protein, ratTrpc6 protein, ratTRPC Cation Channels

Identifiers

PMID22699894
PMCPMC3390208
OpenAlexW1965868120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.